Abstract: With the discovery in the last 3 years of novel Janus kinase 2 (JAK2) and thrombopoietin receptor (MPL) mutations, the pathogenetic understanding of and clinical practice for myeloproliferative neoplasms (MPNs) have entered a new era. Each one of these newly discovered mutations, including JAK2V617F, MPLW515L, and a JAK2 exon 12 mutation, has been shown to result in constitutive activation of JAK-STAT signaling and also induce a MPN phenotype in mice. Thus, JAK2 is now considered to be a legitimate target for drug development in MPNs, and small molecule JAK2 inhibitors have already gone through successful preclinical testing, and early-phase human trials in primary myelofibrosis have already begun. Furthermore, JAK2 mutation screening has now become a front-line diagnostic test in the evaluation of both "erythrocytosis" and thrombocytosis and the 2001 World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis have now been revised to incorporate JAK2V617F mutation screening.
T he term "myeloproliferative disorders" (MPDs) was first introduced by William Dameshek in 1951 1 when he underscored the similarities among chronic myelogenous leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) in their bone marrow histology and clinical presentation. According to the upcoming revised World Health Organization (WHO) classification system for hematopoietic tumors, these 4 clinicopathologic entities are now included in the broader category of myeloproliferative neoplasms (MPNs). The 4 "classic" MPNs (CML, PV, ET, and PMF) should be distinguished from the other "nonclassic" MPNs including chronic neutrophilic leukemia, chronic eosinophilic leukemia, hypereosinophilic syndrome, systemic mastocytosis, and "MPNs, unclassifiable."
Analysis of X chromosome inactivation patterns in informative females as well as other cytogenetic and/or molecular studies have long established both classic and nonclassic MPNs as clonal stem cell disorders. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] In 1960, Nowell and Hungerford 12 described the BCR-ABL mutation harboring the Philadelphia (Ph 1 ) chromosome in CML and by 1990, retroviral infection of hematopoietic stem cells with P210 BCR-ABL was shown to induce CML-like disease in mice. [13] [14] [15] Since then, additional MPN-specific mutations have been identified and include FIP1L1-PDGFRA and chromosomal translocations involving PDGFRB or FGFR1 in molecularly defined myeloid malignancies associated with eosinophilia and systemic mastocytosis-associated KIT mutations. 16 Most recently, 3 distinct types of gain-of-function mutations were described in classic, BCR-ABL-negative MPNs: JAK2V617F in PV, ET, and PMF [17] [18] [19] [20] ; JAK2 exon 12 mutations in PV 21, 22 ; and MPLW515L/K in PMF and ET. 23, 24 
JAK2, MPL, AND JAK-STAT SIGNALING
Humans are believed to express more than 500 protein kinases, broadly classified into tyrosine or serine/threonine protein kinases. 25 Protein tyrosine kinases (PTKs) are particularly relevant to MPN pathogenesis and are further classified into receptor and cytoplasmic PTKs. 25, 26 Among the 90 or so known PTK genes; 58 encode for receptor and 32 for cytoplasmic PTKs. 27 Examples of MPN-relevant receptor PTKs include platelet-derived growth factor receptor (PDGFR), stem cell factor receptor (KIT), fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR), and fms-related tyrosine kinase 3 (Flt3). Examples of cytoplasmic PTKs include the Janus family of kinases (JAK1, JAK2, JAK3, and TYK2), the Src family of kinases (SFKs), and ABL kinase.
JAK2 is located on chromosome 9p24 and, like other JAKs, is characterized by the presence of 2 homologous kinase domains; JAK homology 1 (JH1) and 2 (JH2), the former with and the latter without kinase activity. JAK2 mediates signaling downstream of cytokine receptors, including MPL, which is the receptor for thrombopoietin. The human TPO gene is located at chromosome 3q27, 28 and the MPL gene is located at chromosome 1p34. 29 Under normal conditions, JAK-STAT activation is initiated by ligand-receptor binding that induces receptor dimerization, which results in auto-and transphosphorylation of the receptor and associated JAK2. The phosphorylated residues on the receptor subsequently serve as docking sites for the recruitment and activation (by phosphorylation) of signal transducers and activators of transcription (STATs), which in turn dimerize and translocate into the nucleus where interaction with specific regulatory elements induces target gene transcription.
JAK-STAT signaling is regulated at multiple levels by distinct mechanisms including direct dephosphorylation of JAK2 by specific protein tyrosine phosphatases (such as SHP-1), proteolytic degradation of JAK2 through binding with a family of suppressors of cytokine signaling (SOCS), and inhibition of DNA binding of STAT by protein inhibitors of activated STAT (PIAS). 16 
JAK2 AND MPL MUTATIONS IN MPNS
In the context of hematopoiesis, JAK-STAT signaling is crucial for definitive erythropoiesis as well as the cytokine response by myeloid progenitors. 30, 31 It is therefore not surprising that mutations of molecules associated with JAK-STAT signaling or its regulators have been associated with hematologic malignancies. Earlier examples of such mutations include ETV6-JAK2 that is associated with t(9;12)(p24; p13) described in acute lymphoblastic leukemia as well as atypical CML. 32, 33 Most recently, 2 other JAK2 fusion mutants were described: PCM1-JAK2, which is karyotypically evident as t(8;9)(p22;p24) and is associated with atypical MPD, acute leukemia, or T cell lymphoma 34 -37 ; and BCR-JAK2, which is karyotypically evident as t(9;22)(p24;q11.2) and is associated with atypical MPD. 38 The association of JAK2V617F with MPNs, including PV, ET, and PMF, was first reported in 2005. [17] [18] [19] [20] Since then, the mutation has also been described, at a lower frequency, in a spectrum of other myeloid disorders including nonclassic MPNs and other chronic myeloid neoplasms including MDS. 39, 40 JAK2V617F is not found in lymphoid disor- Diagnosis requires the presence of both major criteria and one minor criterion or the presence of the first major criterion together with 2 minor criteria.
*Hemoglobin or hematocrit Ͼ99th percentile of method-specific reference range for age, sex, altitude of residence or hemoglobin Ͼ17 g/dL in men, 15 g/dL in women if associated with a documented and sustained increase of at least 2 g/dL from an individual's baseline value that can not be attributed to correction of iron deficiency, or elevated red cell mass Ͼ25% above mean normal predicted value.
From Tefferi et al (2007), with permission. 54 ders, [41] [42] [43] [44] solid tumors, [45] [46] [47] or secondary myeloproliferation. 48, 49 JAK2V617F is a G to T exon 14 somatic mutation resulting in valine to phenylalanine substitution at codon 617. In general, a high JAK2V617F allele burden might be essential for acquisition of the PV phenotype in vivo; this is accomplished by mitotic recombination that leads to homozygosity for JAK2V617F. [17] [18] [19] Unlike the case with JAK2V617F, the other 2 sets of mutations associated with MPNs are restricted to patients with PV (JAK2 exon 12 mutations) 21, 22 or PMF/ET (MPLW515L/K). 23, 24 JAK2 exon 12 mutations include both in-frame deletions and point mutations. MPLW515L represents a G to T transition at nucleotide 1544, resulting in a tryptophan to leucine substitution at codon 515 of the MPL receptor. Both exon 14 (ie, JAK2V617F) and exon 12 JAK2 mutations induce cytokine-independent cell line proliferation and a PV-like disease in mice. In contrast, MPLW515L induces a PMF-like disease in mice. Regardless, both JAK2 and MPL mutations result in hyperactivation of JAK-STAT signaling and are therefore vulnerable to inhibition by a JAK2 antagonist. 16 
IMPACT OF JAK2V617F ON THE DIAGNOSIS OF THE CLASSIC MPNS
Because neither hemoglobin level nor hematocrit is accurate enough to reflect the true status of the erythrocyte volume in an individual patient, it is possible that an increased hematocrit/hemoglobin level might represent either true polycythemia (ie, associated with increased erythrocyte volume) or apparent polycythemia (not associated with increased erythrocyte volume). True polycythemia may represent either PV or nonclonal erythrocytosis (ie, secondary polycythemia) that is often, but not always, mediated by erythropoietin (Epo). Apparent polycythemia may result from either a reduction in plasma volume (relative polycythemia) or an inaccurate perception of an elevated erythrocyte volume that results from not appreciating high normal values of hematocrit. The term "inapparent PV" is used to describe PV patients in whom increased erythrocyte volume is masked by "normal" hematocrit because of a concomitant increase in plasma volume. 50 Therefore, in a patient suspected of having PV, one has to exclude both secondary and apparent polycythemia, whereas the possibility of inapparent PV should be entertained in the presence of the characteristic clinical features of PV, regardless of the hematocrit level.
In the past, either the Polycythemia Vara Study Group (PVSG) or the 2001 WHO criteria were used for diagnosis of PV. 51, 52 The recent discovery of the almost invariable association between PV and a JAK2 mutation (either JAK2V617F or a JAK2 exon 12 mutation) 53 has led to revised WHO diagnostic criteria for PV that incorporate JAK2 mutation screening (Table  1) . 54 In routine clinical practice, one should start with both JAK2V617F mutation screening and serum Epo measurement when PV is suspected (Fig. 1) . 55, 56 A positive mutation test is highly suggestive of the diagnosis, especially if accompanied by a subnormal serum Epo level. Approximately 5% of patients with PV are JAK2V617F-negative. 53 Therefore, in a JAK2V617F-negative patient with either a high clinical suspicion of PV or a subnormal serum Epo level, the possibility of exon 12 JAK2 mutations should be entertained and pursued. †Requires the failure of iron replacement therapy to increase hemoglobin level to the PV range in the presence of decreased serum ferritin. Exclusion of PV is based on hemoglobin and hematocrit levels and red cell mass measurement is not required.
‡Requires the absence of relevant reticulin fibrosis, collagen fibrosis, peripheral blood leukoerythroblastosis, or markedly hypercellular marrow for age accompanied by megakaryocyte morphology that is typical for PMF-small to large with an aberrant nuclear/cytoplasmic ratio and hyperchromatic, bulbous, or irregularly folded nuclei and dense clustering.
§Requires the absence of BCR-ABL.
Requires absence of dyserythropoiesis and dysgranulopoiesis. ¶Causes of reactive thrombocytosis include iron deficiency, splenectomy, surgery, infection, inflammation, connective tissue disease, metastatic cancer, and lymphoproliferative disorders. However, the presence of a condition associated with reactive thrombocytosis does not exclude the possibility of essential thrombocythemia if the first 3 criteria are met.
From Tefferi et al (2007), with permission. 54 
TABLE 3. Revised WHO Criteria for PMF
Major criteria 1. Presence of megakaryocyte proliferation and atypia,* usually accompanied by either reticulin and/or collagen fibrosis, or, in the absence of significant reticulin fibrosis, the megakaryocyte changes must be accompanied by an increased bone marrow cellularity characterized by granulocytic proliferation and often decreased erythropoiesis (ie, pre-fibrotic cellular-phase disease) 2. Not meeting WHO criteria for PV, † CML, ‡ MDS, § or other myeloid neoplasm 3. Demonstration of JAK2V617F or other clonal marker (eg, MPLW515L/ K), or in the absence of a clonal marker, no evidence of bone marrow fibrosis due to underlying inflammatory or other neoplastic diseases Minor criteria 1. Leukoerythroblastosis ¶ 2. Increase in serum lactate dehydrogenase level ¶ 3. Anemia ¶ 4. Palpable splenomegaly ¶ Diagnosis requires meeting all 3 major criteria and 2 minor criteria. *Small to large megakaryocytes with an aberrant nuclear/cytoplasmic ratio and hyperchromatic, bulbous, or irregularly folded nuclei and dense clustering.
†Requires the failure of iron replacement therapy to increase the hemoglobin level to the PV range in the presence of decreased serum ferritin. Exclusion of PV is based on hemoglobin and hematocrit levels. Red cell mass measurement is not required.
‡Requires the absence of BCR-ABL. §Requires absence of dyserythropoiesis and dysgranulopoiesis. Secondary to infection, autoimmune disorder or other chronic inflammatory condition, hairy cell leukemia or other lymphoid neoplasm, metastatic malignancy, or toxic (chronic) myelopathies. It should be noted that patients with conditions associated with reactive MF are not immune to PMF and the diagnosis should be considered in such cases if other criteria are met.
¶Degree of abnormality could be borderline or marked. From , with permission. 54 Tefferi
The 2001 WHO diagnostic criteria for ET and PMF have also been recently revised by the WHO (Tables 2 and 3) . 54 Unlike the case with PV, JAK2V617F mutation screening plays a minor role in the diagnosis of ET and PMF, which is based primarily on bone marrow histology 57 ; characteristic changes include hypercellularity, an increased number of dysplastic megakaryocytes including cluster formation, and bone marrow stromal changes including myelofibrosis. 58 In general, I also advise baseline bone marrow examination for all patients with PV although the procedure is not essential for making the diagnosis and its prognostic value has not been systematically studied. Similarly, cytogenetic findings in BCR-ABL-negative MPNs are not specific enough to warrant diagnostic utility but are nevertheless obtained to confirm an underlying clonal myeloproliferation. 57 
IMPACT OF JAK2V617F ON THE PROGNOSIS AND TREATMENT OF THE CLASSIC MPNS
In general, neither the presence of JAK2V617F nor its allele burden has been shown to influence survival or leukemic/fibrotic transformation in ET, PV, or PMF. 59 -66 Similarly, the results of published studies on relationship between thrombosis and JAK2V617F have not been consistent enough to warrant definitive conclusions. 65 Therefore, at present, I do not use JAK2V617F information for either prognostic or therapeutic purposes. Instead, new information suggests a prognostic value of leukocytosis for overall survival in both ET 64 and PV, 67 for leukemic transformation in PV, 67 and for thrombosis in both PV 67 and ET. 64 In Table 4 , I have summarized current risk-adapted treatment strategies in ET, PV, and PMF. Phlebotomy is the only form of treatment modality that is believed to provide improved survival for patients with PV. However, results of a recent study have challenged the need for aggressive phlebotomy in aspirin-treated patients with hematocrit values that range between 40% and 55%. 70 Nevertheless, for now, I recommend keeping the hematocrit level at Ͻ45%. In addition, all patients with PV should receive daily low-dose aspirin in the absence of contraindications for aspirin use. 71 The additional benefit of cytoreductive therapy in PV, in terms of reducing thrombosis risk, was suggested by the early PVSG studies. 72 However, the danger of long-term drugassociated complications has restricted use of these drugs to high-risk patients only (Table 4) . At present, hydroxyurea is my drug of choice for use in high-risk patients with PV. The potential value of alfa interferon therapy requires validation in a controlled setting. 73 It is reasonable to expect near-normal survival in the majority of patients with ET, especially in the absence of leukocytosis, regardless of specific treatment. 64 Furthermore, the relatively low incidence rates of thrombosis and hemorrhage as well as the occurrence of both short-term and long-term drug side effects are the basis for carefully selecting patients with ET who require specific treatment (Table 4) . In other words, at present, I use cytoreductive therapy in ET only in the presence of risk factors for thrombosis including advanced age (Ն60 years) or history of major thrombosis. In particular, I do not treat extreme thrombocytosis per se in the absence of aspirin-resistant symptoms. 74 If cytoreductive therapy is indicated, then it is important to note that only hydroxyurea, as a treatment agent, has been shown in a prospective study to be associated with a reduced risk of thrombosis in ET. 75 Hydroxyurea was also found to be superior to anagrelide in a head-to-head comparative study of high-risk patients with ET. 76 The concern regarding hydroxyurea leukemogenicity in ET is currently unsubstantiated 64 , and the indiscriminate use of new drugs that have not been tested in a controlled setting is unwarranted.
Among the BCR-ABL-negative classic MPNs, PMF has the worst prognosis with an approximate median survival of 5 years. 77 However, several studies have identified both clinical and laboratory parameters that are used to identify good-risk as well as high-risk patient categories. 78 The most important indicators of adverse prognosis are the presence of anemia (hemoglobin Ͻ10 g/dL), advanced age (Ͼ64 years), hypercatabolic symptoms (weight loss, profound fatigue, night sweats, and low-grade fever), leukocytosis (Ͼ30,000/ L) or leukopenia (Ͻ4000/L), circulating blast cells (Ն1%), high-risk cytogenetic abnormalities (ϩ8, 12pϪ), peripheral blood monocyte count of Ն1,000/L, and platelet count of Ͻ100,000/L. 68,76,78 -81 Table 4 outlines the Mayo Clinic prognostic scoring system for PMF and the corresponding treatment options for each risk category. 68 The 
THE FUTURE
Whether or not small molecule drugs that target JAK2 will be active as well as safe for use in patients with PMF or the related MPNs remains to be seen, and early-phase clinical trials have already begun. 84, 85 At the same time, based on well-demonstrated treatment activity of thalidomide and lenalidomide in PMF, a new immunomodulatory drug, pomalidomide, is currently being evaluated for similar or better therapeutic activity. 86 These are, therefore, exciting times for MPN clinical investigators and their patients and in preparation for uniform reporting of response rates to these new drug trials in PMF, the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) has recently published consensus criteria. 87 At this point we are at a therapeutic crossroads and what happens next depends heavily on the results of the aforementioned ongoing clinical trials.
